CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
about
Closing the door to human immunodeficiency virus.Package of NDV-pseudotyped HIV-Luc virus and its application in the neutralization assay for NDV infection.Targeting chemokines in proteinuria-induced renal disease.Targeting CCR5 for anti-HIV research.Comparison of lentiviruses pseudotyped with S proteins from coronaviruses and cell tropisms of porcine coronaviruses.CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.Brain Invasion by CD4(+) T Cells Infected with a Transmitted/Founder HIV-1BJZS7 During Acute Stage in Humanized Mice.Extracts of medicinal herb Sanguisorba officinalis inhibit the entry of human immunodeficiency virus type one.Gut-homing Δ42PD1(+)Vδ2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1 infection.Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides.Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.
P2860
Q30428089-B56A7505-B345-4D32-B51E-C2F89ECC3915Q35189635-B53CE1DD-6030-43CB-A96F-EBAF10E11E5DQ38026076-C721C8B0-9F7F-42A7-B0BE-9DB9DFFE040FQ38229805-92853A09-6B61-4ADC-9E74-DDFE1AD3617EQ38791544-5DF88926-F24C-4255-B792-FF772DDA4DE8Q38803127-F0D73651-021C-4255-9931-45DE4D46A314Q38912920-554BA233-A0E8-4485-BA2A-C3477540A123Q39178352-F2E0B9CC-CF26-4E87-9C3E-9736E8285F52Q40083110-993011CB-592B-4F9E-85E2-312045C545E7Q41051936-6D5A2F42-4614-4AA9-9950-BDC0EC81C29EQ52692811-3C110EAE-A486-4C7D-AD02-7AA4A1E801CC
P2860
CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
CCR5 antagonist TD-0680 uses a ...... tion, and a resistant variant.
@ast
CCR5 antagonist TD-0680 uses a ...... tion, and a resistant variant.
@en
type
label
CCR5 antagonist TD-0680 uses a ...... tion, and a resistant variant.
@ast
CCR5 antagonist TD-0680 uses a ...... tion, and a resistant variant.
@en
prefLabel
CCR5 antagonist TD-0680 uses a ...... tion, and a resistant variant.
@ast
CCR5 antagonist TD-0680 uses a ...... tion, and a resistant variant.
@en
P2093
P2860
P356
P1476
CCR5 antagonist TD-0680 uses a ...... tion, and a resistant variant.
@en
P2093
Allen K L Cheung
Bojian Zheng
Haibo Wang
Jianguo Liang
Terrence C K Lau
P2860
P304
16499-16509
P356
10.1074/JBC.M112.354084
P407
P577
2012-03-23T00:00:00Z